IV iron administration

PreclinicalSmall molecule

UUniversity of Roma La Sapienza

IV iron administration is one of 42 small molecule programs targeting Anemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

AnemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

2 2

Soliris

AstraZeneca

Phase 3

1 3

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

9 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 5

Vafseo

AAkebia Therapeutics

Phase 3

4 6

Omontys

Takeda

Phase 3

9 7

Campath

GGenzyme, a Sanofi Company

Phase 3

2 8

Alkeran

AApotex Inc.

Phase 3

1 9

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

2 10

Sodium Nitroprusside

WWatson Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ANot yet recruiting

Anemia

NCT07485023

Clinical

Trials by Indication[1]

Pregnancy1 trial

Newborn Phosphocalcic Metabolism After Intravenous Iron Administration During Pregnancy

Completed·UUniversity Hospital, Geneva··NCT06108258·43 enrolled

Anemia1 trial

Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation

Not yet recruiting·UUniversity of Roma La Sapienza·N/A·NCT07485023·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IV iron administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV iron administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV iron administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Roma La Sapienza company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Roma La Sapienza

IV iron administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Pregnancy1 trial

Anemia1 trial

References

Drug Info

Quick Facts

Related News